Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses whether the US patent system is likely to see reform in the near future.
Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how she coordinates with providers on biosimilar switching programs.
Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses ongoing research on biosimilar rituximab, Rixathon.
Kashyap Patel, MD, discusses how biosimilars impact cost in the Medicare Part B context.
Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Denmark has engaged with patients on biosimilars.
Alexandra Valenti, JD, associate at Goodwin, discusses the future of the Biologics Price Competition and Innovation Act (BPCIA) in light of challenges to the Affordable Care Act.
Rolf Benirschke, chief executive officer of Legacy Health Strategies, discusses the challenges patients face in getting access to biologics to treat inflammatory bowel disease. 
Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the impact that biosimilars have made on patient access to therapy.
Kashyap Patel, MD, discusses the need for provider education on biosimilars.
Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the benefits that biosimilars have in terms of patient access.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.